Engineering cures for autoimmune diseases.

Tr1X is developing a novel class of regulatory T cell-based therapies to cure autoimmune and inflammatory diseases and transform patient lives.

Clinical Trials
Our Approach

We combine cutting-edge genetic engineering and deep immunology expertise to pioneer scalable curative therapies for inflammation and autoimmunity.

How it works

Therapies to restore homeostasis

Our novel regulatory T cell-based therapeutics mimic the function of naturally occurring Type 1 regulatory T (Tr1) cells. Designed to restore immune tolerance, our therapies aim to stop severe autoimmune and inflammatory diseases in their tracks.

Program Highlights

Targeted immune modulation, at scale

Targeted & Localized
High Stability, Low Plasticity
Homing & Induction
Targeted & Localized Immune Suppression

Our cells produce suppressive cytokines directly within inflamed tissues while preserving healthy immune responses.

High Stability, Low Plasticity

Engineered for durability, our cells remain stable and functional even in inflammatory environments.

Homing & Induction of De-novo Tregs:

Our therapies migrate to sites of inflammation, modulate effector responses, and drive formation of new Tr1 cells.

Relentlessly dedicated to improving patient lives

We are pursuing breakthrough innovations in autoimmunity, driven by a world-class team committed to transforming the treatment of devastating diseases.


life at Tr1X

Help us reimagine how autoimmune diseases are treated

We are a team of scientists, doctors, engineers and builders driven by curiosity and compassion.

Join us as we build a new path for patients living with autoimmune and inflammatory conditions.

Latest news

Get the latest on our research, progress and partnerships.

Tr1X Announces FDA Clearance of IND Application for TRX319, a First-in-Class Allogeneic CAR-Tr1 Treg Cell Therapy for Progressive Multiple Sclerosis, and $50 Million in Additional Financing

On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026 TRX319 is an allogeneic CAR-Tr1 Treg cell therapy...

Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?

Despite significant advances in biologic and small molecule treatments and

Opportunities for Treg cell therapy for the treatment of human disease

Regulatory T (Treg) cells are essential for maintaining peripheral tolerance,